BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

250 related articles for article (PubMed ID: 33815744)

  • 1. Aristolochic acid-associated urinary tract cancers: an updated meta-analysis of risk and oncologic outcomes after surgery and systematic review of molecular alterations observed in human studies.
    Kang YC; Chen MH; Lin CY; Lin CY; Chen YT
    Ther Adv Drug Saf; 2021; 12():2042098621997727. PubMed ID: 33815744
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Aristolochic acid mutational signature defines the low-risk subtype in upper tract urothelial carcinoma.
    Lu H; Liang Y; Guan B; Shi Y; Gong Y; Li J; Kong W; Liu J; Fang D; Liu L; He Q; Shakeel M; Li X; Zhou L; Ci W
    Theranostics; 2020; 10(10):4323-4333. PubMed ID: 32292497
    [No Abstract]   [Full Text] [Related]  

  • 3. Aristolochic acid-containing Chinese herbal medicine and upper urinary tract urothelial carcinoma in Taiwan: a narrative review.
    Dickman KG; Chen CH; Grollman AP; Pu YS
    World J Urol; 2023 Apr; 41(4):899-907. PubMed ID: 35867141
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of aristolochic acid exposure on oncologic outcomes of upper tract urothelial carcinoma after radical nephroureterectomy.
    Zhong W; Zhang L; Ma J; Shao S; Lin R; Li X; Xiong G; Fang D; Zhou L
    Onco Targets Ther; 2017; 10():5775-5782. PubMed ID: 29255365
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of Genomic Characterization in Upper Tract Urothelial Carcinoma and Urothelial Carcinoma of the Bladder.
    Yang K; Yu W; Liu H; Ding F; Zhang Y; Zhang Y; Wang W; Lou F; Cao S; Wang H; He Z
    Oncologist; 2021 Aug; 26(8):e1395-e1405. PubMed ID: 34050578
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinicopathological characteristics and outcomes of synchronous renal cell carcinoma and urothelial carcinoma: A population-based analysis.
    Wu K; Liu X; Wang Y; Wang X; Li X
    Front Public Health; 2022; 10():994351. PubMed ID: 36388369
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Molecular profiles and urinary biomarkers of upper tract urothelial carcinomas associated with aristolochic acid exposure.
    Karanović S; Ardin M; Tang Z; Tomić K; Villar S; Renard C; Venturini E; Lorch AH; Lee DS; Stipančić Ž; Slade N; Vuković Brinar I; Dittrich D; Karlović K; Borovečki F; Dickman KG; Olivier M; Grollman AP; Jelaković B; Zavadil J
    Int J Cancer; 2022 Jan; 150(2):374-386. PubMed ID: 34569060
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comprehensive genomic profiling of upper tract urothelial carcinoma and urothelial carcinoma of the bladder identifies distinct molecular characterizations with potential implications for targeted therapy & immunotherapy.
    Tang Q; Zuo W; Wan C; Xiong S; Xu C; Yuan C; Sun Q; Zhou L; Li X
    Front Immunol; 2022; 13():1097730. PubMed ID: 36818471
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Aristolochic acid containing herbs induce gender-related oncological differences in upper tract urothelial carcinoma patients.
    Xiong G; Yao L; Hong P; Yang L; Ci W; Liu L; He Q; Gong K; Li X; Zhou L
    Cancer Manag Res; 2018; 10():6627-6639. PubMed ID: 30584358
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Latency period of aristolochic acid-induced upper urinary tract urothelial carcinoma.
    Jhuang JR; Chiu PC; Hsieh TC; Chen CH; Pu YS; Lee WC
    Front Public Health; 2023; 11():1072864. PubMed ID: 36969664
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bladder Recurrence Following Upper Tract Surgery for Urothelial Carcinoma: A Contemporary Review of Risk Factors and Management Strategies.
    Mertens LS; Sharma V; Matin SF; Boorjian SA; Houston Thompson R; van Rhijn BWG; Masson-Lecomte A
    Eur Urol Open Sci; 2023 Mar; 49():60-66. PubMed ID: 36793750
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Oncologic Outcomes of Kidney-sparing Surgery Versus Radical Nephroureterectomy for Upper Tract Urothelial Carcinoma: A Systematic Review by the EAU Non-muscle Invasive Bladder Cancer Guidelines Panel.
    Seisen T; Peyronnet B; Dominguez-Escrig JL; Bruins HM; Yuan CY; Babjuk M; Böhle A; Burger M; Compérat EM; Cowan NC; Kaasinen E; Palou J; van Rhijn BW; Sylvester RJ; Zigeuner R; Shariat SF; Rouprêt M
    Eur Urol; 2016 Dec; 70(6):1052-1068. PubMed ID: 27477528
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Distinct patterns and behaviour of urothelial carcinoma with respect to anatomical location: how molecular biomarkers can augment clinico-pathological predictors in upper urinary tract tumours.
    Yates DR; Catto JW
    World J Urol; 2013 Feb; 31(1):21-9. PubMed ID: 22986906
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of neoadjuvant and adjuvant chemotherapy for localized and locally advanced upper tract urothelial carcinoma: a systematic review and meta-analysis.
    Quhal F; Mori K; Sari Motlagh R; Laukhtina E; Pradere B; Rouprêt M; Necchi A; Moschini M; Shariat SF
    Int J Clin Oncol; 2020 Jun; 25(6):1037-1054. PubMed ID: 32206939
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lymph node dissection for upper tract urothelial carcinoma: A systematic review.
    Chan VW; Wong CHM; Yuan Y; Teoh JY
    Arab J Urol; 2020 Jul; 19(1):37-45. PubMed ID: 33763247
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Risk factors and treatment outcomes of new contralateral upper urinary urothelial carcinoma after nephroureterectomy: the experiences of a large Chinese center.
    Fang D; Zhang L; Li X; Xiong G; Chen X; Han W; He Z; Zhou L
    J Cancer Res Clin Oncol; 2014 Mar; 140(3):477-85. PubMed ID: 24469253
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prevalence, clinicopathological features, and prognosis in upper tract urinary carcinoma patients with severe preoperative chronic kidney disease.
    Bao Z; Du Y; Yuan Y; Zhu Y; Qian C; Zhan Y; Fang D; Xiong G; Zhang L; Li X; Zhou L
    Transl Androl Urol; 2019 Dec; 8(6):641-650. PubMed ID: 32038960
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecular Characterization of Upper Tract Urothelial Carcinoma in the Era of Next-generation Sequencing: A Systematic Review of the Current Literature.
    Hassler MR; Bray F; Catto JWF; Grollman AP; Hartmann A; Margulis V; Matin SF; Roupret M; Sfakianos JP; Shariat SF; Faltas BM
    Eur Urol; 2020 Aug; 78(2):209-220. PubMed ID: 32571725
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The prognostic value of the Controlling Nutritional Status score on patients undergoing nephrectomy for upper tract urothelial carcinoma or renal cell carcinoma: a systematic review and meta-analysis.
    Chen J; Cao D; Peng Z; Song P; Liu Z; Yang L; Wang L; Zhou J; Wei Q; Dong Q
    Br J Nutr; 2022 Jul; 128(2):217-224. PubMed ID: 34338171
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.